|What is fcoTHIN
fcoTHIN is a proprietary blend of fucoxanthin, derived from seaweed and a virgin, cold-pressed pomegranate oil. The blend, called Xanthigen utilizes uniquely effective means for extracting fucoxanthin from seaweed and then blends it with the highest quality pomegranate oil in unique proportions in order to create a patent pending formula.
A. The Discovery of Xanthigen
Dr. Ramazanov is the inventor of Xanthigen and is credited with determining how to effectively use the blend as a dietary supplement for the promotion of weight management. Dr. Ramazanov, a recognized expert in bioreactive agricultural methodology, spent many years studying marine vegetables also known as seaweed, in order to develop a dietary supplement that would help improve the health of mankind. After years of study, Dr. Ramazanov came to believe that seaweed, consumed as a regular part of the Japanese diet, had a significant bearing on the superior health experienced in Japan. He applied his expertise to the cultivation of seaweed and to the extraction of fucoxanthin from it, in order to create a stable, highly concentrated distillation of fucoxanthin.
In 2005, an important Japanese study demonstrating fucoxanthins thermogenic effects in rodents was published (the Japanese Study). This study and its findings served to reinforce Dr. Ramazanovs long held beliefs. According to the study, attached hereto as Exhibit 2, fucoxanthin increased the metabolic processes in cells, making them burn more fuel to produce energy, a process commonly known as thermogenesis. The study found that fucoxanthin raised the metabolic rate, reduced white adipose tissue (fat), and decreased the overall body weight of rodents - particularly in their abdominal region.
Dr. Ramzanov, convinced he was on the verge of a significant breakthrough, initiated studies in humans in 2006. Dr. Ramazanovs theories were tested in two separate studies, both performed by a highly reputable and independent third party research institute. Both studies met the gold standard for clinical testing (randomized, double-blind, placebo controlled) and both utilized Dr. Ramazanovs proprietary Xanthigen blend, testing the exact same formula and dosage of Xanthingen present in fcoTHIN. One of the studies was designed to evaluate the energy expenditure (metabolic rate) of humans as affected by Xanthigen. This study was titled, the Metabolic Rate Study. The other study evaluated the actual weight and inches lost by humans taking Xanthigen and was titled, the Weight Loss Study.
B. The Studies and their Findings
A total of 150 women participated in these studies: 40 in the Metabolic Rate Study and 110 in the Weight Loss Study. The average age of the women in the group was 38 and all participants were clinically obese. Both studies lasted 16 weeks, and in both all the participants were counseled to follow an 1800 calorie diet. Because there was a particular interest on fucoxanthins effects on white adipose tissue that comprises human visceral fat1, the groups within the weight loss study were further broken down into two sub-groups: 1) those with Non-Alcoholic Fatty Liver Disease (NAFLD), and 2) those who did not suffer from Non-Alcoholic Fatty Liver Disease (NFL) fatty liver disease.
The Metabolic Rate Study concluded that there was a statistically significant difference between the group taking Xanthingen and the placebo control group. They found:
The group taking Xanthigen (fcoTHIN) experienced an increase in energy expenditure rate (also known as Metabolic Rate) of 7.03 units Kelvin as measured at the conclusion of the sixteen week study. The Placebo group experienced an increase in energy expenditure of 5.95 units Kelvin. Therefore, the group taking Xanthigen (fcoTHIN) had a metabolic rate increase that averaged 18.2% higher than the Placebo group.
The placebo groups baseline metabolic rate at the beginning of the study was 5.91 units Kelvin and, as described above, 5.95 units Kelvin at the conclusion, an average increase over baseline of under 1%.
Researchers first noted an increase in human metabolic rate after the 5th full week of the study.
The study noted that pomegranate seed oil has a supportive or synergistic effect on the fucoxanthin-induced stimulation of the human metabolism. The researchers went on to explain that the pomegranate seed oil has been shown to suppress delta-9 de-saturation, suggesting that this is a possible mechanism behind the effect of the pomegranate seed oil on hepatic TG accumulation. The Weight Loss Study made similar statistically significant findings:
There were two groups who took Xanthigen (fcoTHIN) in this study: those with non-alcoholic fatty liver disease (NAFLD) and those with normal liver fat (NLF). The group with NAFLD lost an average of 15.2 pounds while the group with NLF lost an average of 13.9 pounds. The average of both groups which is the entire study group taking Xanthigen lost an average of 14 lbs The placebo group only lost 3lbs.
Mathematically, those who took fcoTHIN lost over 4 times more weight than those who just dieted. In addition, waist circumference was significantly reduced in those taking Xanthigen versus the placebo. The study determined that Xanthigen (fcoTHIN) promotes weight loss, body and liver fat content reduction in obese non-diabetic female subjects independently of their liver fat content.
The first statistically significant reduction in body weight occurred after 6 continuous weeks of supplementation. Researchers concluded that the results of this clinical trial indicate that Xanthigen possesses clinically relevant anti-obesity properties.
Researches noted that pomegranate seed oil reduced the serum levels of monounsaturated fatty acids that predominanty form fat depots in the body. These fat depots have been implicated in cardiovascular disease, obesity and diabetes. As an additional benefit, the study determined that Xanthigen is an effective anti-inflammatory.
Life Science Alliance (LSA), a respected and independent consortium of scientific consultants, reviewed the two clinical studies together with the Japanese study in rodents. Some of their significant findings included:
All three studies were well designed in a reasoned and scientific manner
With respect to the Metabolic Rate Study, LSA concluded that the authors were able to detect statistically significant differences among the treatments on measures of [energy expenditure rate], which from the data presented, appear to be valid. LSA concluded that Xanthigen is safe and non-stimulant.
With respect to the Weight Loss Study, LSA found that the study supported the conclusion that Xanthigen (fcoTHIN) results in weight loss, reduction in waist circumference and reductions in other biomarkers of obesity.
Lastly, LSA noted that amongst the 150 participants, over the 16 week period, no adverse effects were experienced. The Science of fcoTHIN-induced Thermogenesis
The term, thermogenic, is euphemistically referred to as fat burning because of the nature in which the process works. In thermogenesis, the metabolic rate of cells in increased, requiring them to burn fat that the body stores in adipose tissue. This is completed when the conversion of nutrients (such as fat) to energy occurs within the cells, more specifically, inside cell structures called mitochondria.
Fucoxanthin (fcoTHIN) induced thermogenesis is non-stimulant in nature because it bypasses adrenergic (stimulatory or sympathetic) receptors at the surface of the cells that are also known to be UPC-1 inducing. Instead, it addresses the process of energy distribution at the level of mitochondria, precisely where conversion of fat into energy is taking place. This process was demonstrated by all of the studies cited in this memo human and animal.
fcoTHIN is particularly effective at burning visceral fat, composed of white adipose tissue. Visceral fat is the fat surrounding the internal organs, and specifically the double layer of fat flanking the stomach, called the omentum. (This is specifically different from subcutaneous fat which lies just below the surface from the skin and is more often deposited in the hip and thigh regions.) An excess of visceral fat leads to the "pot belly" or "beer belly" effect, in which the abdomen protrudes excessively.
In the Japanese Study, researchers determined that supplementation with fucoxanthin dramatically reduced the abdominal fat of mice.(4) Building upon these findings, researchers in the Metabolic Rate study noted that the fucoxanthin found in fcoTHIN directly contributed to the reduction of visceral fat in humans. It accomplishes this by igniting the production of a specialized protein gene called uncoupling protein-1 (UCP1 Gene) in white adipose tissue. (Visceral fat is made up of white adipose tissue.5) The researchers believe that the UCP1 Gene stimulates the metabolism of fatty acids inside of the white adipose tissue and thereby speeds their oxidation. This metabolic process results in burning the visceral fat tissue.
Note: fcoTHIN does not contain ephedra or caffeine, or host of other ingredients typically present in stimulant based thermogenic nutrition products including bitter orange, guarana, ma huang or any other type of caffeine. None of the components of fcoTHIN work by affecting the central nervous system.
Note: fcoTHIN has added benefits due to its nature as a caratenoid. Carotenoids are antioxidants that provide cells protection from free radical damage. Several studies have citied the antioxidant properties of fucoxanthin. In one study, the authors concluded that fucoxanthin exhibits antioxidant activities comparable to that of alpha-tocopherol (i.e. Vitamin E).
It is important to note that fcoTHIN is the only fucoxanthin product available in health food stores and online supported by human clinical studies. Other so-called fucoxanthin thermogenic supplements may not be able to rely on the Japanese Study and certainly cannot claim the efficacy of our human studies. The unique process in which our fucoxanthin is derived and its concentration tested is explained in detail in each of our human studies and the researchers conducting the Metabolic Rate Study found that the pomegranate seed oil in our patent pending fcoTHIN formula increased fucoxanthins effectiveness as a fat burner.
Serving Size: 1 Softgel
Servings Per Container 90
Amount Per Serving - % Daily Value
Xanthigen Proprietary Blend 200mg *
Brown Seaweed Fucoxanthin Concentrate
(Undaria Pinnatifida, Laminaria japonica)
Pomegranate Seed Oil
* Daily Value not established
Other Ingredients: Gelatin, glycerin, palm oil, purified water. Contains naturally occurring iodine.
Suggested Use: 1 softgel 3 times daily (3 total) with meals and 8 oz. of water.
Advanced Usage: Healthy Individuals may increase gradually to 3 softgels, 3 times daily (9 total) with food and at least 8 oz. of water.
Clinical studies indicate an average of 6 weeks of use before significant thermogenic response is experienced. Give fucoTHIN at least 8 full weeks to begin to notice change.
The statements included above have not been evaluated by the FDA or Total Health. This product is not intended to diagnose, treat, cure or prevent any disease.